N-methyl-4-{[2-(naphthalen-2-ylamino)-quinazolin-6-yl]oxy}pyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-methyl-4-{[2-(naphthalen-2-ylamino)-quinazolin-6-yl]oxy}pyridine-2-carboxamide
• 英文别名: N-methyl-4-[2-(naphthalen-2-ylamino)quinazolin-6-yl]oxypyridine-2-carboxamide
• 化学式: C₂₅H₁₉N₅O₂
• 分子量: 421.458
• InChiKey: GEPWGPXBAOSQHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-methyl[4-(2-methylsulfonylquinazolin-6-yloxy)(2-pyridyl)]carboxamide 、 2-萘胺 以 乙腈 为溶剂， 生成 N-methyl-4-{[2-(naphthalen-2-ylamino)-quinazolin-6-yl]oxy}pyridine-2-carboxamide
  参考文献：
  名称：

  2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase

  摘要：

  提供了新的替代喹唑啉、喹喔啉、喹啉和异喹啉化合物、组合物以及在人类或动物主体中抑制Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。

  公开号：

  US20050085482A1

文献信息

• 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Ramurthy Savithri

  公开号：US20090317359A1

  公开（公告）日：2009-12-24

  New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本文提供了新的取代喹唑啉、喹喔啉、喹啉和异喹啉化合物、组合物和抑制人或动物主体中Raf激酶活性的方法。这些新化合物组合物可单独使用，也可与至少一种额外药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
  申请人：Novartis Vaccines and Diagnostics, Inc.

  公开号：US07691866B2

  公开（公告）日：2010-04-06

  New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代喹唑啉、喹喔啉、喹啉和异喹啉化合物、组合物和抑制人或动物主体中Raf激酶活性的方法。这些新化合物和组合物可单独使用或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR THE TREATMENT OF CANCER
  申请人：CHIRON CORPORATION

  公开号：EP1680122A1

  公开（公告）日：2006-07-19
• US7691866B2
  申请人：——

  公开号：US7691866B2

  公开（公告）日：2010-04-06
• [EN] 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER<br/>[FR] QUINOXALINES, QUINOLINES, ISOQUINOLINES ET QUINAZOLINES 2,6-BISUBSTITUEES SERVANT D'INHIBITEURS A LA KINASE RAF POUR LE TRAITEMENT DU CANCER
  申请人：CHIRON CORP

  公开号：WO2005037285A1

  公开（公告）日：2005-04-28

  New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds of formulae (I)-(IV), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. The substituents are defined in the claims.